Talk:Breast cancer

The purpose of this page is to record, in reverse chronological order, conversations about content changes for the accompanying main page.

April 2018

• User:Herminafernandes: In follow up to our meeting last week, I do want to make a clarification that the q3 week paclitaxel is strictly relevant in the metastatic breast cancer setting only, both based on data as well as current practice patterns, national and international guidelines. In the adjuvant setting, regimens for dose dense/q2 week paclitaxel and weekly paclitaxel are current standard of care and reflect current guidelines and practice patterns.
  • User:Jwarner: Noted, will move adjuvant q3wk paclitaxel to the historical page and metastatic q3wk paclitaxel back to the main page.
• User:Jwarner: Inquiry sent to authors of the TANIA trial:

Dear Prof. von Minckwitz,

We have recently been adding the chemotherapy regimens described in the TANIA trial Lancet Oncology publication to the HemOnc.org breast cancer page: https://hemonc.org/wiki/Breast_cancer. I have a few questions that I was hoping you could help clarify:

1. For the regimens with a weekly option (paclitaxel; nab-paclitaxel; doxorubicin; epirubicin; vinorelbine) are these drugs to be given every week or are there rest periods, for example a 3 weeks out of 4 dosing? We have seen both especially for the taxanes, so wanted to clarify.
2. If there are no rest periods for the weekly regimens, was the bevacizumab given every 2 weeks or every 3 weeks? Or was either an option?
3. When a range of doses is specified (e.g., paclitaxel 80-90 mg/m2 weekly), do you mean that any dose within that range could be used, or is it meant to indicate that a dose of 80 mg/m2 or 90 mg/m2 could be used, in this example? The reason I ask is that we try to minimize the number of regimens on the website where a range of doses is given.

We really appreciate your consideration of this request for clarification.